Characteristics and applications of avatrombopag tablets/sucoxin

Avatrombopag is an oral small-molecule thrombopoietin receptor agonist (TPO-RA). It promotes the proliferation and maturation of megakaryocytes by selectively activating TPO receptors, thereby increasing the number of platelets in peripheral blood. Its unique pharmacological mechanism makes it important in the treatment of thrombocytopenia, especially for patients who undergo invasive procedures due to chronic liver disease, as well as patients with chronic immune thrombocytopenia (ITP) who have insufficient response to previous treatments. Unlike first-generation TPO-RAs such as recombinant human TPO protein, avatrombopag does not cause the production of anti-TPO antibodies, so the risk of immunogenicity is low and it is suitable for long-term use.

Avatrombopag has significant clinical advantages, and its onset of effect is relatively fast, with platelet levels generally starting to rise within 4 to 7 days after taking it. It is suitable for short-term use before surgery. The dosage is set more accurately based on the platelet baseline value. For patients with chronic liver disease, the medication can be started 10 to 13 days before surgery and platelet elevation can be achieved for 5 consecutive days without the need for intravenous platelet transfusion, which significantly reduces the risk of transfusion-related complications. For patients with chronic ITP, the starting dose is 20 mg per day, which can be gradually adjusted to a maximum of 40 mg according to platelet levels. Clinical observations show that it maintains stable platelet counts, reduces the frequency of bleeding events, and helps improve patients' long-term prognosis and quality of life.

In terms of pharmacokinetics, avatrombopag is mainly metabolized by the liver's CYP2C9 and CYP3A metabolic enzyme systems. Food can increase its bioavailability, so it is recommended to take it with food to optimize absorption. However, it also suggests the need to evaluate potential drug interactions in patients taking concomitant medications. In clinical trials and real-world use, avatrombopag is generally well tolerated. Common adverse reactions include headache, fatigue, nausea, increased ALT, etc. Although thrombotic events are the focus, the incidence rate is relatively low, especially under correct dosage control, the risk is controllable.

Reference materials:https://go.drugbank.com/drugs/DB11995